2seventy bio (TSVT) Competitors

2seventy bio (NASDAQ:TSVT) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Do institutionals and insiders believe in TSVT or XFOR?

93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 7.2% of 2seventy bio shares are held by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media refer more to TSVT or XFOR?

In the previous week, X4 Pharmaceuticals had 8 more articles in the media than 2seventy bio. MarketBeat recorded 14 mentions for X4 Pharmaceuticals and 6 mentions for 2seventy bio. 2seventy bio's average media sentiment score of 0.62 beat X4 Pharmaceuticals' score of -0.06 indicating that 2seventy bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
2seventy bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, TSVT or XFOR?

2seventy bio has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Does the MarketBeat Community prefer TSVT or XFOR?

X4 Pharmaceuticals received 54 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 68.10% of users gave X4 Pharmaceuticals an outperform vote while only 45.45% of users gave 2seventy bio an outperform vote.

Company	Underperform	Outperform
2seventy bio	Outperform Votes 25 45.45%	Underperform Votes 30 54.55%
X4 Pharmaceuticals	Outperform Votes 79 68.10%	Underperform Votes 37 31.90%

Which has stronger valuation & earnings, TSVT or XFOR?

X4 Pharmaceuticals has lower revenue, but higher earnings than 2seventy bio. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
2seventy bio	$37.86M	6.88	-$217.57M	-$1.12	-4.45
X4 Pharmaceuticals	$2.56M	254.69	-$101.17M	-$0.19	-19.74

Do analysts recommend TSVT or XFOR?

2seventy bio currently has a consensus price target of $5.60, indicating a potential upside of 12.45%. X4 Pharmaceuticals has a consensus price target of $85.00, indicating a potential upside of 2,166.67%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than 2seventy bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
2seventy bio	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.29
X4 Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is TSVT or XFOR more profitable?

X4 Pharmaceuticals has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
2seventy bio	-207.25%	-53.65%	-23.67%
X4 Pharmaceuticals	N/A	-236.19%	-75.14%

Summary

X4 Pharmaceuticals beats 2seventy bio on 10 of the 19 factors compared between the two stocks.